2Sanders CC, Barry AL, WT, et al . Detection of extended-spectram β-lactamases-producing members of the family enterobacteriaceae with the VITEKESBLs Test [J]. J Clin Microbiol, 1996, 34 (12): 2997-3001.
5Jacoby GA, Han P. Detection of extended-spectruma β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia Coli [J], J Clin Microbial, 1996, 34 (4): 908-911.
3[1]CDC, National Nosocomial Infections Surveillance(NNIS) System report, Data summary from October 1986-April 1998; issyed June 1998[J]. Am J Infect Control, 1998,26: 522-533
4[2]Gales AC, Jones RN, Turnidge J, et al. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999[J].Clin Infect Dis,2001,32(Suppl 2): 146-155
5[3]Harris AD, Smith D, Johnson JA, et al. Risk factors for imipenem-resistant pseudomonas aeruginosa among hospitalized patients [J]. Clin Infect Dis, 2002,34: 340-345
6[4]Busher KH, Cullmann W, Dick W, et al. Imipenem resistance in pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein[J]. Antimicrob Agents Chemother,1987,31 : 703-708
7[5]Pai H, Kim J, Kim J, et al. Carbapenem resistance mechanisms in pseudomonas aeruginosa clinical isolates [J]. Antimicrob agents chemother,2001,45:480-484
8Nordmann P, Naas T. Sequence analysis of PER-I extended-spectrum beta-lactamase from pseudomonas a eruginosa and comparison with class A beta-lactamases. Antimicrob Agents Chemother, 1994,38 : 104-114.
9Vahaboglu H, Ozturk R, Aygun G, et al. Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomical Acinetobacter and Pseudomonas aeruginosa isolates in Turkey :a nationwide multicenter study .Antimicrob Agents Chemother , 1997,40:2265 -2269.
10Luzzaro F, Mantengoli E, Perilli M, et al. Dynamics of a noscomical outbreak of multidrug -resistant Pseudomonas aeruginosa producing the PER-1 extended -spectrum beta-lactamases.J Clin Microbiol,2001,39 : 1865-1870.
2Surina G, Quale JM, Manikal VM, et al. Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage pattems[ J ]. J Antimicrob Chemother, 2000, 45 (6): 895-898.
3Noriyuki N, Naohiro S, Yuko S, et al. Nosocomial outbreak of infec-tion by proteus mirabilis that produces extended - spectrum CTX-M-2 type B - lactamase[ J]. J Clin Mierobiol, 2003, 41 ( 12):5530-5536.
4Biendo M, Thamas D. Molecular diversity of proteus mirabilis isolates producing extended - spectrum β- lactamases in a French university hospital [ J ]. Clin Microbiol Infec, 2005, 11 (5):395-401.
5Surina G, Quale JM, Manikal VM, et al. Antimierobial resistance in Enterobacteriaccae in Brooklyn, NY: epidemlology and relation to antibiotic usage paltems. J Antimierob Chemotuer, 2000, 45(6): 895-898.
6Biendo M, Thamas D. Molecular diversity of proteus mirabilis isolates producing extended-spectum {3-1actamases in a French university hospital. Clin Microb Infec, 2005, 11(5 ) : 395-401.
7Tangden T, Cars O, Melhus A, et al. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamas- es : a prospective study with Swedish volunteers [ J ]. Anti- microb Agents Chemother, 2010,54 ( 9 ) : 3564-3568.
8Siedelman L, Kline S, Dural S. Risk factors for commu- nity- and health facility-acquired extended-spectrum β- lactamase-producing bacterial infections in patients at the University of Minnesota medical center [ J ]. Am J Infect Control, 2012,40(9) :849-853.
9Sutter D E, Bradshaw L U, Simkins L H. High incidence of multidrug-resistant gram-negative bacteria recovered from Afghan patients at a deployed US military hospital [ J ]. Infect Control Hosp Epidemiol, 2011,32 ( 9 ) : 854- 860.
